Proper attention to ๐—ฎ๐—น๐—น aspects of pathology in COVID19, simultaneously, is paramount to proper treatment:

๐Ÿ”ฅpulmonary endothelium
โฌ†๏ธโฌ‡๏ธ
๐Ÿ”ฅplatelets

Products of platelet-endothelial activation:

โšก๏ธthrombi
โšก๏ธplatelet-derived mediators
SARS-CoV-2 causes a double-whammy state of ๐—ฝ๐—น๐—ฎ๐˜๐—ฒ๐—น๐—ฒ๐˜ ๐—ฎ๐—ฐ๐˜๐—ถ๐˜ƒ๐—ฎ๐˜๐—ถ๐—ผ๐—ป and ๐—ฝ๐˜‚๐—น๐—บ๐—ผ๐—ป๐—ฎ๐—ฟ๐˜† ๐—ฒ๐—ป๐—ฑ๐—ผ๐˜๐—ต๐—ฒ๐—น๐—ถ๐—ฎ๐—น ๐—ฑ๐—ฒ๐˜€๐˜๐—ฎ๐—ฏ๐—ถ๐—น๐—ถ๐˜‡๐—ฎ๐˜๐—ถ๐—ผ๐—ป:

๐Ÿ”ฅpericyte loss
โฌ‡๏ธ
๐Ÿ”ฅunstable pulm endothelium
โฌ‡๏ธโฌ†๏ธ
๐Ÿ”ฅplatelet activation
Pericyte loss of the pulmonary endothelium due to SARS-CoV-2 leads to endothelial destabilization, which in turn activates MKs and platelets maturing and residing in the pulmonary capillary spaces.
In addition to endothelial activation by inducing pericyte loss, SARS-CoV-2 attaches to platelets via a number of identified (e.g. CD147, etc) receptors, inducing ๐—ฒ๐˜ƒ๐—ฒ๐—ป ๐—ณ๐˜‚๐—ฟ๐˜๐—ต๐—ฒ๐—ฟ ๐—ฝ๐—น๐—ฎ๐˜๐—ฒ๐—น๐—ฒ๐˜ ๐—ฎ๐—ฐ๐˜๐—ถ๐˜ƒ๐—ฎ๐˜๐—ถ๐—ผ๐—ป, independent of its endothelial activation actions.
In addition to this direct viral action on platelets, there are likely other pathways that lead to further delayed platelet activation, including ๐—บ๐—ถ๐—บ๐—ถ๐—ฐ๐—ธ๐—ฟ๐˜† of host pro-aggregant factors, and ๐—ฎ๐˜‚๐˜๐—ผ๐—ฎ๐—ป๐˜๐—ถ๐—ฏ๐—ผ๐—ฑ๐—ถ๐—ฒ๐˜€ that further activate platelets.
To best approach a severe COVID19 infection, one must recognize the ๐—ต๐—ฎ๐—น๐—น๐—บ๐—ฎ๐—ฟ๐—ธ ๐—ณ๐—ฒ๐—ฎ๐˜๐˜‚๐—ฟ๐—ฒ๐˜€ of COVID19 and potential targets for intervention.
To ๐—บ๐—ฒ๐—ฟ๐—ฒ๐—น๐˜† ๐˜๐—ฎ๐—ฟ๐—ด๐—ฒ๐˜ ๐˜๐—ต๐—ฟ๐—ผ๐—บ๐—ฏ๐—ถ formation by DOACs, and ignore the need to address

(1) endothelial activation
(2) platelet activation
(3) potent ๐—ฝ๐—น๐—ฎ๐˜๐—ฒ๐—น๐—ฒ๐˜ ๐—บ๐—ฒ๐—ฑ๐—ถ๐—ฎ๐˜๐—ผ๐—ฟ๐˜€ released during platelet activation

most likely will be ๐—ถ๐—ป๐—ฎ๐—ฑ๐—ฒ๐—พ๐˜‚๐—ฎ๐˜๐—ฒ therapy
DOAC montherapy reduces the burden of existing and forming thrombi.

But it will *๐—ป๐—ผ๐˜* exert endothelial stabilization effects that would be present with heparin.

๐—ฃ๐—น๐—ฎ๐˜๐—ฒ๐—น๐—ฒ๐˜ ๐—บ๐—ฒ๐—ฑ๐—ถ๐—ฎ๐˜๐—ผ๐—ฟ๐˜€ ๐—บ๐—ฎ๐˜† ๐—ฎ๐—ฐ๐—ฐ๐˜‚๐—บ๐˜‚๐—น๐—ฎ๐˜๐—ฒ, including serotonin and angiogenic factors.
๐—›๐—ฒ๐—ฝ๐—ฎ๐—ฟ๐—ถ๐—ป products have the added benefit of endothelial stabilization, and thereby, reduce feed-forward platelet activation that would stem from endothelial factors

Avoiding VILI with lung protective ventilation (low TV, avoid overzealous PEEP) further protects endothelium
In certain cases (such as late presenters, or those on DOAC or VKA monotherapy), ๐™ฅ๐™ก๐™–๐™ฉ๐™š๐™ก๐™š๐™ฉ ๐™ข๐™š๐™™๐™ž๐™–๐™ฉ๐™ค๐™ง๐™จ ๐™–๐™˜๐™˜๐™ช๐™ข๐™ช๐™ก๐™–๐™ฉ๐™ž๐™ค๐™ฃ may be ๐—ฎ๐˜€ ๐—ผ๐—ฟ ๐—ฒ๐˜ƒ๐—ฒ๐—ป ๐—บ๐—ผ๐—ฟ๐—ฒ ๐—ฝ๐—ฎ๐˜๐—ต๐—ผ๐—น๐—ผ๐—ด๐—ถ๐—ฐ ๐—ฎ๐—ป๐—ฑ ๐—ฑ๐—ฒ๐˜๐—ฟ๐—ถ๐—บ๐—ฒ๐—ป๐˜๐—ฎ๐—น as gas exchange abnormalities encountered in COVID19
One such platelet mediator is serotonin. Plasma serotonin is kept at tightly regulated low levels by storing 95% of body's serotonin in platelet granules

Serotonin is uniquely positioned to ๐—ฎ๐—ฐ๐—ฐ๐˜‚๐—บ๐˜‚๐—น๐—ฎ๐˜๐—ฒ in COVID19, as it's released copiously and its reuptake is impaired.
There is clear evidence of plasma serotonin ๐—ฒ๐˜…๐—ฐ๐—ฒ๐˜€๐˜€ in COVID19, with this excess being a result of platelet degranulation, combined with the pulmonary vasculopathy and endothelial dysfunction of COVID19, the same endothelium that is responsible for reuptake of serotonin.
It is paramount to understand the signs of serotonin toxicity, and to recognize that there is ๐—ผ๐˜ƒ๐—ฒ๐—ฟ๐—น๐—ฎ๐—ฝ between ARDS / sepsis and the signs of serotonin toxicity

Distinguishing signs of serotonin toxicity include
- Myoclonus
- Hyperreflexia
- Severe agitation
- Diarrhea
As it pertains to COVID19, the signs of serotonin toxicity that may occur due to *๐™ฉ๐™๐™š ๐™™๐™ž๐™จ๐™š๐™–๐™จ๐™š ๐™ž๐™ฉ๐™จ๐™š๐™ก๐™›* without presence of culprit meds include the following:

Some of these may also *๐—ป๐—ผ๐˜* be necessarily explained by a run-of-the-mill sepsis or ARDS picture
In cases where specific signs of serotonin toxicity may be present (ankle clonus, severe agitation, diarrhea), ๐˜€๐—ฒ๐—ฟ๐—ผ๐˜๐—ผ๐—ป๐—ถ๐—ป ๐—ถ๐—ป๐—ต๐—ถ๐—ฏ๐—ถ๐˜๐—ถ๐—ผ๐—ป may be necessary.

The answer to such cases is to ๐™ฉ๐™š๐™–๐™จ๐™š ๐™ค๐™ช๐™ฉ the specific signs of serotonin toxicity and act accordingly
In case serotonin toxicity is suspected and pathognomonic signs are detected, serotonin inhibition can be relatively safely performed with Cyproheptadine

Please remember that patient does *not* necessarily need to have a culprit medication to harbor serotonin toxicity in COVID19
And more important than inhibition of serotonin in a disease such as COVID19 inherently prone to buildup of serotonin, it's best to ๐—ฎ๐˜ƒ๐—ผ๐—ถ๐—ฑ it by avoiding the culprits (e.g. Fentanyl, VILI) and instead addressing platelet-endothelial activation beyond just DOACs (e.g. heparin)
It is a ๐—ฑ๐—ถ๐˜€๐˜€๐—ฒ๐—ฟ๐˜ƒ๐—ถ๐—ฐ๐—ฒ to the patients when we attribute signs of unrecognized serotonin toxicity to "it's just COVID" ๐Ÿ˜ข

Unexplainable agitation, hallucination, tachypnea, fever, explosive diarrhea, myoclonus, hyperreflexia ๐—ฑ๐—ฒ๐˜€๐—ฒ๐—ฟ๐˜ƒ๐—ฒ a thinking๐Ÿค 

๐Ÿ”‘ is to recognize.
You can follow @farid__jalali.
Tip: mention @twtextapp on a Twitter thread with the keyword โ€œunrollโ€ to get a link to it.

Latest Threads Unrolled:

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.